Request for Free Sample

Blood Screening Market Overview and Scope

The Blood Screening Market size was valued at USD 3.34 billion in 2024 and is expected to reach USD 8.16 billion by 2032, growing at a CAGR of 11.88% over the forecast period of 2025-2032.

The global blood screening market is growing rapidly due to the increase in the number of transfusion-transmissible infections (TTIs) such as HIV, Hepatitis B, Hepatitis C, and syphilis, and the need for blood donation screening. The demand for safe blood is on the rise, along with blood donations, and technological advances, including NAT and ELISA testing. Rising government regulations and healthcare initiatives to improve blood safety are also believed to fuel the market growth. Automation, digitalization, and the incorporation of state-of-the-art diagnostics are also improving the accuracy and efficacy of testing in blood banks and hospitals globally.

The U.S. blood screening market size was valued at USD 0.95 billion in 2024 and is expected to reach USD 2.24 billion by 2032, growing at a CAGR of 11.36% over the forecast period of 2025-2032.

The U.S. is the dominating country in the North American blood screening market due to the strong healthcare infrastructure, high investment in healthcare, mainly in blood services, and a high number of blood donors and increased cases of infections in the country. Such superiority is also enhanced by next-generation public–private partnerships, early adoption of new genomics testing and ELISA technology, and a favorable reimbursement environment that promotes the use of novel screening tools.

Blood Screening Market Dynamics

Drivers

  • Increasing Incidence of Transfusion-Transmittable Infections (TTIs) to Drive the Market

Rising burden of TTIs such as HIV, Hepatitis B, Hepatitis C, and syphilis is significantly driving the traction of the blood screening market growth. Millions of individuals need blood transfusions every year to save lives, and the risk of transmitting these infections through the administration of insufficiently screened and unscreened blood products remains a significant public health threat. It has further raised the alert among medical practitioners and authorities about the need for complete testing. This is driving countries to enhance their blood safety procedures and impose higher testing standards to avoid disease transmission, thereby surging demand for sophisticated blood screening products.

The International Society of Blood Transfusion reported in 2024 that NAT detected >3,100 NAT-positive donations in 2019 alone, with >22,000 overall since NAT introduction—mostly being HBV— signaling the ongoing global burden of TTIs and the importance of continuing to employ sensitive screening techniques.

  • Technological Advancements in Screening Techniques are Boosting Market Growth

The new screening technologies currently under development are further evolving testing speed, accuracy, and the ability to screen for infections earlier. Nucleic acid testing (NAT), for example, can detect pathogens during the window period before antibodies have been produced and therefore significantly enhances the safety of blood. Likewise, NGS and multiplex platforms allow identification of more than one infection from a single sample. Integrated software systems-driven automated platforms are helping to continue to make workflow processes in blood banks and hospitals more efficient as well. Such technological enhancements not only contribute to better performance of the tests but also promote the use of the test using shorter assay times and lower labour costs, and thus are well suited for high-throughput applications.

Automation and integrated platforms are proliferating through government–industry partnerships. For instance, in May 2024, New York Blood Center Enterprises and Thermo Fisher announced a high-throughput blood-genotyping array to enhance matching precision in transfusions.

Restraint

  • The Expensive Advanced Screening Technologies are Limiting the Growth of the Market

The blood screening market trends are also restrained by the cost of integrating novel testing technologies, including nucleic acid testing (NAT), next-generation sequencing (NGS), and fully automated analyzers. Those systems come with a high upfront cost — not just for the machine, but also for the company’s proprietary reagents, routine service calls, and software updates.

More costly are infrastructure changes, such as temperature-controlled rooms and the ability to back up the power to manage testing 24 hours a day. At many particularly low- and middle-income blood banks, the annual fee is not feasible. However, the economic constraints associated with these technologies have restricted the use of high-throughput sensitive screening methodologies and resulted in the use of outdated low-sensitivity methods of screening for disease, such as rapid testing and manual ELISA, that compromise the overall quality and safety of the blood supply.

Blood Screening Market Segmentation Analysis

By Product & Service

The reagents & kits segment dominated the blood screening market share in 2024 with a 74.20%, as reagents and kits are crucial for routine and high-throughput testing activities. These are required to be used for the implementation of assays such as NAT, ELISA, rapid diagnostics, etc., that are used for screening the transfusion-transmissible infections, including HIV, Hepatitis B, and Hepatitis C. The repeat purchase nature of the consumables for every screening process results in the continuous demand from all blood banks and diagnostic laboratories. Moreover, the improvement of reagent formulation, enhancement of reliability, and the ready-to-use kits in the market are some of the major factors contributing to the rapid expansion of this segment, which is gaining pace in the global ARTs market.

The instruments segment is projected to grow at the highest CAGR during the forecast period, due to the growing automation and digitalization of blood screening processes. There is an increasing demand for high-throughput and fully automated analyzers, particularly in large blood banks and hospitals, where they can help increase efficiency, decrease manual mistakes, and shorten turnaround time. Multiplexing approaches and state-of-the-art detection technologies (e.g., chemiluminescence immunoassays, real-time PCR) also reinforce the trend towards more complex devices.

By Technology

The nucleic acid test segment of the blood screening market has the highest market share in 2024, with a 40.30%, as it has higher sensitivity and specificity to detect transfusion-transmissible infections (TTIs) such as HIV, Hepatitis B, and Hepatitis C at an early stage in 2024. NAT can detect viral RNA or DNA in the window of period during which the antibody is not detectable, which greatly diminishes the possibility of transmitting the infection through blood transfusion. Its wide acceptance in developed countries, due to strict regulatory concerns and to secure its blood supplies, means that NAT has become a gold standard in blood screening. Its short run time and ability to be interconnected with autoanalyzers also make it an efficient test in high-throughput settings.

The next-generation sequencing segment is expected to witness the fastest growth over the forecast period as it can offer complete and high-throughput blood sample analysis. NGS allows for the simultaneous identification of multiple pathogens and mutations, and genetic markers in a single test, rendering it of great interest for advanced blood safety applications and the identification of rare pathogens. With the cost of sequencing decreasing and bioinformatics tools becoming more widely available, NGS is emerging as a popular assay in both clinical and research applications. Furthermore, its application in personalized medicine and epidemiological monitoring makes NGS a revolutionary technology for the future of blood screening.

By End User

The blood banks segment held the largest share in the blood screening market in 2024, with a 78.69%. Blood banks are significant centers for the collection, processing, and storage of blood and blood components. These centers are obligated to ensure all donated blood is tested for a range of transfusion-transmissible diseases, including HIV, Hepatitis B, Hepatitis C, and syphilis. Blood banks process a high number of samples per day, so it is important to have a permanent use of high-sensitivity techniques such as NAT and ELISA. Moreover, many national government policies and mandates in all markets demand strict testing of blood banks before any transfusion, so the blood bank stands out as a key player in the market.

The hospitals segment is projected to grow at the highest CAGR during the forecast period, owing to the rising number of surgeries, trauma cases, and blood transfusion procedures. Since hospitals are interested in enhancing the safety of their patients and decreasing the risks of infection, many of them are initiating on-site blood screening, especially in the case of large and tertiary care institutions. Integration with automated systems and point-of-care diagnostics is also increasing accessibility and efficiency for blood screening in the hospital.

Blood Screening Market Regional Insights

North America dominated the blood screening market with a 37.43% market share in 2024, as it has developed a healthcare system, a strong blood donation culture, and favorable rules for TTIs from regulatory authorities. The growth of the market in this region is fuelled by the focus on early adoption of high-end screening technologies such as NAT and CLIA, especially in the U.S. and Canada. Furthermore, the key players being here, robust government support, and the volume of blood transfusions, have also propelled the region to lead the blood safety assurance.

The Asia Pacific region is experiencing the fastest growth with a 12.51% CAGR over the forecast period in the blood screening market analysis due to awareness about blood-borne diseases, the need for safe blood, and growing Healthcare facilities in developing nations. Public health programs are making progress on this new blood screening. China, India, and Japan are funding a lot for the blood screening. Government Acts and Policies are encouraging voluntary blood donations and the use of newer technologies for testing, such as ELISA and NAT. In addition, the increasing prevalence of infectious diseases and large patient base in the region have been boosting the demand for advanced, safe, and large-volume blood testing.

The blood screening market is growing rapidly in Europe due to strict regulatory policies, a rise in the number of surgeries, and increasing demand for safe blood transfusions. Various nations in the region have mandated the screening of infections such as HIV, Hepatitis B, and C, leading to increased penetration of advanced technologies such as NAT and next-generation sequencing. Moreover, the rising knowledge of transfusion safety, robust public health infrastructure, and constant advancements in diagnostic platforms are also driving the steady growth of the market in the region.

Latin America is witnessing the moderate growth of the blood screening market, due to increasing awareness about transfusion-transmissible infections and government efforts to facilitate voluntary blood donation. Countries are enhancing blood safety regulations, which in turn is leveling up the penetration of screening technologies such as ELISA and rapid tests. Limited availability of sophisticated diagnostic infrastructure in rural regions is still a problem.

The Middle East & Africa (MEA) region will witness a gradual growth owing to rising healthcare infrastructure, investment in public health programs, and rising requirements for safe blood due to the high prevalence of diseases. Aided by rollouts of diagnostic technology in various areas of the region, governments are prompting an increase in diagnostic capacity, although high costs of equipment and understaffed personnel are likely to temper the rate of market growth.

Key Companies in the Blood Screening Market

The blood screening market companies are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Grifols S.A., Siemens Healthineers AG, bioMérieux SA, Becton, Dickinson and Company (BD), DiaSorin S.p.A., and other players.

Recent Developments in the Blood Screening Industry

  • April 2024 – Abbott reported that its i-STAT TBI cartridge gained U.S. Food and Drug Administration (FDA) clearance for use with whole blood. This expansion enables clinicians to test patients with suspected traumatic brain injury (TBI) or concussion at the bedside and receive lab-quality results in 15 minutes. The test was previously cleared for plasma or serum, requiring processing in the laboratory and delaying diagnosis.

  • May 2024 – Thermo Fisher Scientific launched a new array-based system for extended blood group research to further increase transfusion safety. This cutting-edge platform is aimed at enabling future innovations in blood compatibility testing and enhancing transfusion medicine outcomes.

    Blood Screening Market Report Scope:
    Report Attributes Details
    Market Size in 2024 USD 3.34 Billion 
    Market Size by 2032 USD 8.16 Billion 
    CAGR CAGR of 11.88% From 2025 to 2032
    Base Year 2024
    Forecast Period 2025-2032
    Historical Data 2021-2023
    Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Product & Service (Reagents & Kits, Instruments, Software & Services)
    • By Technology (Nucleic Acid Test, ELISA, Rapid Tests, Western Blot Assays, Next-generation Sequencing)
    • By End User (Blood Banks, Hospitals)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
    Company Profiles Abbott Laboratories, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter), Grifols S.A., Siemens Healthineers AG, bioMérieux SA, Becton, Dickinson and Company (BD), DiaSorin S.p.A., and other players.